Christina Savva

Christina Savva

Auto-generated profile, based on publicly available information

Christina Savva

Department of Medicine, Integrated Cardio Metabolic Center, Karolinska Institute, Huddinge, Sweden Clinical Department of Endocrinology, Karolinska University Hospital Huddinge, Sweden

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Atherosclerosis
Verified
Journal Article
Closed access
PDF file
SSSara Straniero
Sara Straniero
ALA. Laskar
A. Laskar
CSC. Savva
C. Savva
JHJennifer Härdfeldt
Jennifer Härdfeldt
BAB. Angelin
B. Angelin
MRM. Rudling
M. Rudling

26 May 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
CSChristina Savva
Christina Savva
Luisa A. HelgueroLuisa A. Helguero
Luisa A. Helguero
MGMarcela González-Granillo
Marcela González-Granillo
TMTânia Melo
Tânia Melo
DCDaniela Couto
Daniela Couto
MKMarion Korach-André
Marion Korach-André
Male and female offspring of obese mothers are known to differ significantly in their metabolic adaptation and later development of complications. We investigated the sex-dependent responses in obese offspring of mice with maternal obesity, focusing on changes in liver glucose and lipid metabolism. Maternal obesity prior to and during gestation led to hepatic insulin resistance and inflammation in male offspring, while female offspring were protected. These sex differences were explained by more efficient transcriptional and posttranscriptional reprogramming of metabolic pathways to prevent the damaging effects of maternal obesity in females compared to males. These differences were sustained later in life, resulting in a better metabolic balance in female offspring. In conclusion, sex and maternal obesity drive transcriptional and posttranscriptional regulation of major metabolic processes in offspring liver differently, explaining the sexual dimorphism in obesity-associated metabolic risk.

9 February 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
CSChristina Savva
Christina Savva
Luisa A. HelgueroLuisa A. Helguero
Luisa A. Helguero
MGMarcela González-Granillo
Marcela González-Granillo
TMTânia Melo
Tânia Melo
DCDaniela Couto
Daniela Couto
MKMarion Korach-André
Marion Korach-André
SUMMARY: The prevalence of overweight and obesity among children has drastically increased during the last decades and maternal obesity has been demonstrated as one of the ultimate factors. Nutrition-stimulated transgenerational epigenetic regulation of key metabolic genes is fundamental to the developmental origins of the metabolic syndrome. Fetal nutrition may differently influence female and male offspring. In this work, we investigated the sex-dependent programming of maternal obesity in visceral, subcutaneous and brown adipose tissues of offspring using magnetic resonance imaging and spectroscopy and a lipidomic approach combined with a Smart-Seq2 differential sequencing analysis. We show that the triglyceride profile varies between adipose depots, sexes and maternal diet. Our results demonstrate for the first time that a sex-dependent gene programming exists in visceral, subcutaneous and brown adipose tissues. Maternal obesity differentially programs gene expression in adipose depots of female and male offspring, which may contribute to the sex-dependent metabolic complications later in life. Graphical

8 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
CSChristian Sommerauer
Christian Sommerauer
CGCarlos J. Gallardo-Dodd
Carlos J. Gallardo-Dodd
CSChristina Savva
Christina Savva
LHLinnea Hases
Linnea Hases
MBMadeleine Birgersson
Madeleine Birgersson
CKClaudia Kutter
Claudia Kutter
Introduction: The occurrence of obesity-related hepatic malignancies differs between sexes, suggesting the involvement of sex hormones. Female sex hormones maintain cell homeostasis through estrogen receptor (ER) signaling and protect from developing nonalcoholic fatty liver disease (NAFLD) in mice and humans. Rationale: To understand recovery from high-fat diet (HFD)-induced liver disease in males upon estrogen treatment, we comprehensively characterized molecular changes in the liver upon selective activation of estrogen receptors (ERs) to identify novel therapeutic targets downstream of estrogen signaling. Methods: To dissect hepatic ER isoform-driven responses, we integrated liver transcriptomes from female and male HFD mice treated with or without four different estrogen agonists, along with multiomics data, including bulk, single-cell and spatial transcriptomics, chromatin profiling, machine learning models and advanced microscopy. Patient cohorts and primary human hepatocyte spheroids datasets were included. Results: Only males developed liver steatosis. We found that selective activation of either ERα or ERβ reduced HFD-induced hepatic steatosis in male mice. Systemic ER activation restored HFD-induced aberrant gene expression of cellular processes across liver cell types, including hepatocytes. Profiling of marked histones revealed that ER activation modulated promoter and enhancer sites and identified 68 estrogen-sensitive enhancer-gene pairs. Most of these genes were similarly deregulated in human nonalcoholic fatty liver disease (NAFLD) patients, including the transcription factor TEAD1 . TEAD1 expression increased in NAFLD patients, and inhibiting TEAD ameliorated steatosis in spheroids by suppressing lipogenic pathways. Conclusions: Systemic activation of ERα or ERβ modulates molecular pathways in the liver to counteract NAFLD. Our study identified TEAD1 as a key ER-sensitive gene and suggested that its inhibition poses a therapeutic strategy to combat NAFLD without the undesired side effects elicited by estrogen signaling. Clinical research relevance: We identified drug targets downstream of estrogen signaling, including TEAD1, and demonstrate that TEAD inhibition improves steatosis by suppressing lipogenic pathways. Basic research relevance: The targeted activation of nuclear ERs recovers high-fat diet-induced molecular and physiological liver phenotypes by remodeling core pathways beyond lipid metabolism. ER-responsive enhancers regulate central metabolic genes of clinical significance in NAFLD patients, highlighting the potential impact of this research on understanding liver cell plasticity. HIGHLIGHTS: steatosis in livers of high-fat diet (HFD) male mice was effectively reduced by selective activation of estrogen receptors (ERα and ERβ) with four different agonists. ER agonist treatments successfully reversed HFD-induced changes in gene regulation and expression, revealing new treatment targets involving previously unconnected molecular pathways. estrogen-sensitive enhancers regulated important genes, including TEAD1, emerging as pivotal NAFLD regulators significantly impacting metabolic processes. high TEAD1 gene expression in NAFLD patients correlated with disease severity, underscoring its clinical significance in disease progression. inhibiting TEAD with small molecules alleviated steatosis by suppressing lipogenic pathways, resembling some of the same beneficial effects as estrogen treatment.